PCSK9 and diabetes mellitus: Long-term risk of diabetes-related adverse events was assessed in 10 studies including 24,745 participants treated with PCSK9 inhibitors, and the incidence of diabetes-related adverse events was 4.50% (95% CI, 3.10%–6.50%), when applied the random-effects model (Table 2).